ABSTRACT In an attempt to stimulate Hb F synthesis in baboons by means other than erythropoietic stress, we considered the possibility that an agent that inhibits methylation of CpG sequences in DNA may be effective. 5-Azacytidine, a cytosine analogue that cannot be methylated, is such an agent. Animals whose packed red cell volume was maintained at approximately 20% by bleeding were given 10 daily intravenous injections of the drug (6 mg/kg) in 12 days. Hb F levels in these animals started to increase on day 5 of this regimen and peak levels, which were 6-30 times higher than those produced by bleeding alone, occurred 5-7 days after the last dose of the drug. In animals previously identified as genetically "high" or "low" Hb F responders, the maximal
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The degree of methylation. of CpG dinucleotide sequences of DNA has been shown to be important in the control of gene activity, hypomethylation being. associated with expressed genes (1) (2) (3) (4) . At this time it is not known which CpG sequences at specific positions in the genome are crucial to gene expression. The non-a-globin gene cluster has been recognized as being a suitable model for the investigation ofthis problem because it might be expected that the well-known changes in gene expression during ontogeny (y --8(3) are related to reciprocal changes in methylation. However, both y and P.genes are hypomethylated in human fetal erythropoietic tissue (5) . It therefore is likely that hypomethylation is not the' only factor responsible for the changes in the expression of the globin genes during ontogeny. On the otherhand, the fact that in adult erythropoietic tissue the CpG sequences associated with the 'y regions are methylated suggests that methylation of DNA is a factor involved in the cessation of y chain synthesis (<1%) in the adult (5) .
It also offers an experimental design to test for the possibility that incorporation of 5-azacytidine (5-azaC), an analogue of cytosine that cannot be methylated, into DNA leads to y-globin gene expression in the adult. We have chosen to use this agent in vivo in the baboon because this animal is a suitable model for the study of normal hemoglobin switching (6) and also because the reverse switch in the adult baboon has been shown to respond to erythropoietic stress with an increase in the number of Hb F-containing erythrocytes (F cells) and an increase in Hb F synthesis (7) (8) (9) . The magnitude of this response (high or low) has been shown to be genetically determined (10, 11) and it appeared to be of interest to determine whether these genetic differences could be influenced by 5-azaC. Other myelosuppressive agents [hydroxyurea and 1-f3-D-arabinofuranosylcytosine (araC, cytosine arabinoside)] were used in four, baboons to test their effect on Hb F synthesis. METHODS Initially, four baboons (2, 3, 3, and 5 years old; weight 4-12 kg) were bled to reduce the packed erythrocyte volume (PCV) to 20% within 5 days. Two of the baboons -had been found to be high Hb F responders and two were low responders (10, 11) . The PCV of20% was maintained for another 10 days by bleeding; during this time, Hb F levels were measured every day by alkali denaturation (12) to determine the extent ofHb F increase in each animal due to bleeding alone. There was an adequate reticulocyte response which plateaued at approximately 20%.
5-azaC (6 mg/kg) was injected intravenously on days 15-19 and 22-26. The PCV was maintained at 20% by daily removal of 10-20% ofthe blood volume. Blood cellcounts (includingplatelets) were obtained daily with a Coulter Counter (model S plus). F cell number (percentage oferythrocytes containing reciprocal concentrations of Hb F and Hb A) was determined by the acid elution test (13) . Globin chain synthesis was measured periodically in reticulocytes throughout the experimental period (6). One additional animal, which was not bled, received 5-azaC at 6 mg/kg each weekdayfor 2 weeks (10 injections) to determine whether Hb F increased in nonanemic animals. Hb F levels and synthesis were monitored as above.
After it had been established that 5-azaC at 6 mg/kg stimulated Hb F synthesis, a dose-response relationship was determined as follows. Two high Hb F responders and two low responders were treated with 5-azaC in the same way as the original four animals, except that 1 mg/kg was given daily for 5 days followed by 10 days of bleeding to maintain a PCV of 20%. This schedule then was repeated for dosages of2, 3, and 4 mg/kg.
One animal was treated with hydroxyurea (25-50 mg/kg each weekday for' 2 weeks) to determine whether myelosuppression alone (and achieved by a different molecular mechanism) might be responsible for increased Hb F synthesis. Two animals received hydroxyurea (25-50 mg/kg/day) followed 30 min later by 5-azaC (3 mg/kg) each weekday for 2 weeks. This regimen was used to determine the influence of hydroxyurea (which interferes with DNA synthesis by inhibiting ribonucleoside diphosphate reductase) on the effectiveness of 5- (in which the cytosine ring is normal and the pentose is modified) to determine its effect on Hb F production. The regimen was similar to that for 5-azaC (3 mg/kg daily each weekday for 2 weeks). This animal was subsequently treated with 5-azaC. Thirteen animals were used in this study. All animals except the one that was not bled received adequate amounts of iron dextran, folate, and vitamin B-12.
RESULTS
During the period of bleeding alone (days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , maximal Hb F levels in the high and low responders were 10% and 2%, respectively. Five to 7 days after the initiation of treatment with 5-azaC, Hb F levels started to increase and reached their peaks 5-7 days after discontinuation of the drug. These peak levels were 67% and 81% in the two high responders and 32% and 33% in the two low responders. They were maintained for 5-7 days even though 10-20% of the blood volume was removed daily with the intention of maintaining the PCV at approximately 20%. In the animal for which the Hb F levels are shown in Fig.  1 (Fig. 3) . araC (3 mg/ kg for 10 injections) given to one animal increased Hb F levels from 5% to 18%. When a course of 5-azaC (4 mg/kg each weekday for 10 days) was given afterward, Hb F levels increased to 42%.
DISCUSSION
The data are in keeping with the hypothesis that the increase in Hb F synthesis under the influence of 5-azaC is due to hy- Proc. Nad Acad. Sci. USA 79 (1982) Proc. Nadt Acad. Sci. USA 79 (1982) 4431 the erythropoietic stress due to the combined effect of bleeding and the drug. In addition, after araC is incorporated into DNA, it may be slightly less methylated than the normal nucleotide, as has been suggested by G. P. Beardsley (personal communication).
Hypomethylation ofthe CpG sequences relevant to y-globin gene expression in the adult might lead to a methylation pattern that is similar to that found in the fetus (5), thus allowing y-globin gene expression. Because the relevant 3-globin gene sequences in the adult are hypomethylated, 5-azaC should have no effect on ,3globin production. The prevalence of Y-globin in the 5-azaC-treated adult animals could be explained by the known asynchrony of y and 83 chain synthesis (17, 18) . y-Globin accumulates before 3-globin, and the moderate increase in cell size in the 5-azaC treated animals ( Table 1) could not provide the space for a normal amount of/globin to be accommodated.
From the data it is possible to estimate that the maturation time of erythroid stem cells affected by 5-azaC is 6-12 days which is consistent with the assumption that the modification ofthe DNA takes place in all erythropoietic stem cells and promotes -globin gene expression. The previously described (7) stimulation ofHb F synthesis by erythropoietic stress may have a similar molecular basis, in the sense that methylation may occur during normal maturation, and rapid maturation due to stress erythropoiesis may be associated with hypomethylation. In this respect it is interesting that neither erythropoietic stress nor treatment with 5-azaC obliterates the genetic difference between low and high Hb F responders. Thus, this genetic difference must involve mechanisms other than differential methylation.
The demonstrated effect of5-azaC may have therapeutic implications if similar Hb F increases could be achieved in man-e.g., in sickle cell anemia it might be expected that a high mean corpuscular hemaglobin value for Hb F under the influence of the drug would inhibit sickling (19) . The use of a drug for this purpose, however, must have an acceptable risk/benefit ratio and, therefore, a myelosuppressive agent as 5-azaC is not suitable for this purpose unless it is possible to modify its structure so that its effect on y-globin gene expression can be separated from cytotoxic effects.
